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The most common type of hearing loss results from damage to the cochlea including lost
hair cells (HCs) and spiral ganglion neurons (SGNs). In mammals, cochlear HC loss causes
irreversible hearing impairment because this type of sensory cell cannot regenerate. The
protection from SGN from degeneration has implications for cochlear implant to patients
with severe deafness.This review summarizes the several treatments for HC regeneration
based on experiments. We discuss how transgene expression of the neurotrophic factor
can protect SGN from degeneration and describe potential new therapeutic interventions
to reduce hearing loss.We also summarized viral vectors and introduced the gene and drug
delivery system for regeneration and protection of cochlear HCs. Finally, we introduce the
novel endoscopy we developed for local injection into cochlea.
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POTENTIAL USE OF DRUG AND GENE THERAPY TO AID
REGENERATION OF SENSORY CELLS
Drug, gene and cell therapy are attractive to facilitate regenera-
tion of hair cells (HCs) and spiral ganglion neurons (SGNs). For
endogenous HC regeneration, it is critical to identify potential
stem cells of the inner ear.
Wewill try to regulate the Notch signaling and overexpress pro-
teins, such as Atoh 1, that can increase the regenerative properties
of the sensory epithelium of the cochlea (Zheng and Gao, 2000).
Adenoviral (ADV) vectors can transfect with SCs in vitro (Kanzaki
et al., 2002a) and in vivo (Ishimoto et al., 2002).
When adenovirus containing Atoh 1 gene were transfected into
SCs through endolymph of the mature guinea pig cochlea, HCs
replacement and hearing improvement were observed in some
deaf mammals.
Themembers of theNotch signaling pathway also play key roles
in mediating HC differentiation in the developing cochlea (Jahan
et al., 2013). HC production is regulated by the Notch signaling
pathway in a process called lateral inhibition (Jahan et al., 2013).
Notch-mediated lateral inhibition is critical for cell-fate determi-
nation within HCs and SCs, regulating the number of HCs by
inhibiting HC proliferation.
When Notch signaling is inhibited by a γ-secretase inhibitor,
HC differentiation from inner ear stem cells was observed in
vivo (Mizutari et al., 2013). HC generation resulted from an
increase in the level of Atoh 1 in response to inhibition of Notch
signaling (Jahan et al., 2013). HC regeneration resulted from trans-
differentiation of SCs (Mizutari et al., 2013). Inhibition of Notch
signaling may be a potential therapy to treat severe deafness.
PROTECTION OF NEURAL DEGENERATION
Following profound hearing loss, severe atrophy is found within
the cochlea and central auditory systems. If the peripheral organ
is damaged, the nerve degeneration is a common ﬁnding in the
nervous system (Springer and Kitzman, 1998).
Destruction of IHCs due to trauma or disease leads to the
degeneration of SGNs (Otte et al., 1978; Altschuler et al., 1999),
probably because IHCs normally provide excitatory activation
to the cochlear nerve. Preservation of SGNs, their axons of
cochlear nerve and their connections are necessary to restore audi-
tory function, because degeneration of SGNs should reduce the
effectiveness of hearing aid devices, including cochlear implant.
Chronic cochlear electrical stimulation (ES) after HC loss has
been shown to reduce the irreversible damage of SGNs (Miller
et al., 2002).
Neurotrophic factors and maintenance of synaptic connec-
tivity are important to prevent neuronal degeneration (Springer
and Kitzman, 1998). Brain-derived neurotrophic factor (BDNF)
and/or glial derived neurotrophic factor (GDNF) effectively pro-
mote SGN survival following exposure to deafening noise or
ototoxic drugs (Miller et al., 2002).
Treatmentwith neurotrophic factor such asGDNF signiﬁcantly
enhance SGN survival compared to that in untreated deafened
ears. Combining ES with GDNF overexpression treatment addi-
tionally protects against SGNdegeneration (Kanzaki et al., 2002b).
It suggests that cochlear implant combined with neurotrophic
support may have more effective treatment.
APPROACHES INTO INNER EAR
The inner ear is enclosed by a bony capsule. Such a relative
anatomical isolation makes inner ear an ideal target for thera-
peutic local injection because spread of the injected vector, the
drug, and the transgene to surrounding tissues is expected to be
limited.
We have several approaches into inner ear including via scala
tympani, scala media, or semicircular canal. Scala media approach
would be more effective with cells in organ of Corti, but more
traumatic. It means via scala media approach does not preserve
hearing threshold. Scala tympani approach is less traumatic and
used for prevention of SGN degeneration.
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GENE DELIVERY INTO INNER EAR
Gene delivery or transfer introduces exogenous genes into cells.
As mentioned above, viral vectors are still the efﬁcient vehi-
cles for gene transfer in animal experiments about the inner ear
regeneration.
For inner ear gene transfer, several types of viral vectors such
as ADV, herpes viral (HSV), adeno-associate viral (AAV) (Iizuka
et al., 2008), Sendai virus vectors (SEV) (Kanzaki et al., 2007), have
been applied to different types of cells of the mammals. How-
ever, cytotoxicity and immune response are common complicating
factors in the clinical and experimental use of viral vectors.
DRUG DELIVERY SYSTEM INTO INNER EAR
We describe that treatment for inner ear regeneration and protec-
tion needs local injection into round window membrane (RWM)
in cochlea, but not systemic injections due to systemic side effects.
However, pharmacokinetics of agents locally injected into inner
ear is not well known. Hence, we develop the real time obser-
vation of drug delivery system in transgenic animals in vivo
(Kanzaki et al., 2012a). We observed drug delivery time differ-
ence between local and systemic injections. In local injection,
drugs appeared and disappeared earlier than in systemic injec-
tion. However, delivery time also varied in the local injection
group.
We also ﬁnd that RW niche obstruction such as false mem-
brane or ﬁbrous connective membrane blocked drug delivery into
inner ear. Therefore, observing RW is very important before local
injection of drug into inner ear (Kanzaki et al., 2012a).
NOVEL ENDOSCOPY FOR DRUG DELIVERY
The RWM cannot be visualized in around 30% of all the patients
with hearing loss. In those cases adhesions need to be removed ﬁrst
before local injection is performed.We develop a novel endoscopy
to explore the RWM for the purpose of local injection (Kanzaki
et al., 2012b). The endoscope we develop contains a catheter chan-
nel for delivering drugs and a suction channel. The catheter has a
ﬁne needle, which can be used to remove or perforate RW niche
mucosal adhesions and be used to apply drugs directly onto the
surface of the RWM (Kanzaki et al., 2012b).
CONCLUSION AND FUTURE DIRECTIONS
Themolecular signals that stimulateHCs regeneration and protec-
tion of SGNs have begun to be identiﬁed. Proliferation of HCs has
been achieved in mammals by overexpressing Atoh1, and Notch
inhibitor drugs. The preservation of SGNs is very important and
has implications for cochlear implants. These studies will lead to
therapeutic interventions for the hearing impaired.
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